miR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: A retrospective analysis of the PETACC-8 trial

被引：0
|
作者：
Mathe, Y. Gaston [1 ]
Martin-Lanneree, S. [2 ]
Vazart, C. [2 ]
Fontaine, K. [2 ]
Mulot, C. [3 ]
Caumont, A. [4 ]
Montestruc, F. [4 ]
Le Malicot, K. [5 ]
Lepage, C. [6 ]
Taieb, J. [7 ]
Laurent-Puig, P. [8 ]
机构：
[1] IntegraGen SA, Mol Diagnost, Evry, France
[2] IntegraGen, R&D, Evry, France
[3] INSERM, U1147, Paris, France
[4] Biostat EXYSTAT, Malakoff, France
[5] FFCD, Biostat, Dijon, France
[6] CHU Dijon, Clin Oncol, Dijon, France
[7] Hop European George Pompidou, Dept Gastroenterol & Digest Oncol, Paris, France
[8] Paris Descartes Univ, UMR1147, Paris, France
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
521P
引用
收藏
页码：175 / 175
页数：1
相关论文
共 50 条
  • [21] DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer A Secondary Analysis of the PETACC-8 Randomized Clinical Trial
    Boige, Valerie
    Vincent, Marc
    Alexandre, Philippe
    Tejpar, Sabine
    Landolfi, Stefania
    Le Malicot, Karine
    Greil, Richard
    Cuyle, Pieter Jan
    Yilmaz, Mette
    Faroux, Roger
    Matzdorff, Axel
    Salazar, Ramon
    Lepage, Come
    Taieb, Julien
    Laurent-Puig, Pierre
    JAMA ONCOLOGY, 2016, 2 (05) : 655 - 662
  • [22] DEFECTIVE MISMATCH REPAIR STATUS AS A PROGNOSTIC BIOMARKER OF DISEASE-FREE SURVIVAL IN STAGE III COLON CANCER PATIENTS TREATED WITH FOLFOX ADJUVANT CHEMOTHERAPY
    Zaanan, Aziz
    Flejou, Jean-Francxois
    Emile, Jean-Francxois
    Guetz, Gaetan Des
    Cuilliere-Dartigues, Peggy
    Malka, David
    Lecaille, Cedric
    Validire, Pierre
    Louvet, Christophe
    Rougier, Philippe
    De Gramont, Aimery
    Bonnetain, Franck
    Praz, Francoise
    Taieb, Julien
    ANNALS OF ONCOLOGY, 2011, 22 : v106 - v106
  • [23] Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy
    Zaanan, Aziz
    Flejou, Jean-Francois
    Emile, Jean-Francois
    Des Guetz, Gaetan
    Cuilliere-Dartigues, Peggy
    Malka, David
    Lecaille, Cedric
    Validire, Pierre
    Louvet, Christophe
    Rougier, Philippe
    de Gramont, Aimery
    Bonnetain, Franck
    Praz, Francoise
    Taieb, Julien
    CLINICAL CANCER RESEARCH, 2011, 17 (23) : 7470 - 7478
  • [24] Radiomic signature-based nomogram to predict disease-free survival in stage II and III colon cancer
    Yao, Xun
    Sun, Caixia
    Xiong, Fei
    Zhang, Xinyu
    Cheng, Jin
    Wang, Chao
    Ye, Yingjiang
    Hong, Nan
    Wang, Lihui
    Liu, Zhenyu
    Meng, Xiaochun
    Wang, Yi
    Tian, Jie
    EUROPEAN JOURNAL OF RADIOLOGY, 2020, 131
  • [25] RANDOMISED PHASE III TRIAL OF CAPECITABINE plus OXALIPLATIN VS. BOLUS 5-FU/LV FOR STAGE III COLON CANCER (NO16968): IMPACT OF AGE ON DISEASE-FREE SURVIVAL (DFS) OR OVERALL SURVIVAL (OS)
    Haller, D.
    Cassidy, J.
    Tabernero, J.
    Maroun, J. A.
    De Braud, F.
    Price, T. J.
    van Cutsem, E.
    Hill, M.
    Gilberg, F.
    Schmoll, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 207 - 207
  • [26] The preoperative neutrophil to lymphocyte ratio predicts disease-free survival and overall survival in patients with stage II and III colon cancer
    Absenger, G.
    Szkandera, J.
    Weissmueller, M.
    Postlmayr, U.
    Pichler, M.
    Loibner, H.
    Samonigg, H. S.
    Gerger, A.
    ONKOLOGIE, 2012, 35 : 55 - 56
  • [27] Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset (vol 25, pg 2378, 2014)
    Blons, H.
    Emile, J. F.
    Le Malicot, K.
    Julie, C.
    ANNALS OF ONCOLOGY, 2015, 26 (04) : 822 - 825
  • [28] ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8)
    Laurent-Puig, P.
    Balogoun, R.
    Cayre, A.
    Le Malicot, K.
    Tabernero, J.
    Mini, E.
    Folprecht, G.
    van Laethem, J-L.
    Thaler, J.
    Petersen, L. Norgard
    Sanchez, E.
    Bridgewater, J.
    Ellis, S.
    Locher, C.
    Lagorce, C.
    Rame, J-F.
    Lepage, C.
    Penault-Llorca, F.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial.
    Taieb, Julien
    Emile, Jean-Francois
    Le Malicot, Karine
    Zaanan, Aziz
    Tabernero, Josep
    Mini, Enrico
    Rougier, Philippe
    Van Laethem, Jean Luc
    Bridgewater, John A. Res
    Folprecht, Gunnar
    Salazar, Ramon
    Zawadi, Ayman
    Van Cutsem, Eric
    Lepage, Come
    Laurent-Puig, Pierre
    Blons, Helene
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab (CTX) in resected stage III colon cancer (CC).
    Taieb, Julien
    Tabernero, Josep
    Mini, Enrico
    Subtil, Fabien
    Folprecht, Gunnar
    Van Laethem, Jean-Luc
    Thaler, Joseph
    Bridgewater, John A.
    Sanches, Evaristo
    Petersen, Lone
    Collette, Laurence
    Van Cutsem, Eric
    Le Malicot, Karine
    Rougier, Philippe
    Salazar, Ramon
    Bedenne, Laurent
    Emile, Jean Francois
    Laurent-Puig, Pierre
    Lepage, Come
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345